«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:

24卷

期数:

2018年03期

页码:

192-196

栏目:

出版日期:

2018-05-20

文章信息/Info

Title:

Study on the underlying mechanisms of IL-17A promoting the cisplatin-based resistance of ovarian cancer

作者:

徐灵灵¹; 牛秀珑²; 张宏健³; 李稚君⁴; 陈燕¹; 邓为民¹

1.天津医科大学免疫学系，天津300070；2.中国人民武装警察部队后勤学院附属医院感染性疾病科， 天津300162；3.天津医科大学总医院输血科，天津300052；4.天津医科大学总医院骨科，天津300052

Author(s):

XU Ling-ling¹;  NIU Xiu-long²;  ZHANG Hong-jian³;  LI Zhi-jun⁴;  CHEN Yan¹;  DENG Wei-min¹

1. Department of Immunology, Tianjin Medical University, Tianjin 300070, China; 2. Department of Infectious Diseases, Hospital Affiliated to Logistics College of Chinese People’s Armed Police Forces, Tianjin 300162, China; 3. Department of Blood Transfusion, General Hospital, Tianjin Medical University, Tianjin 300052, China; 4. Department of Orthopedics, General Hospital, Tianjin Medical University, Tianjin 300052, China

关键词:

卵巢癌; IL-17A; 顺铂; 耐药

Keywords:

ovarian cancer;  IL-17A;  cisplatin;  drug-resistance

分类号:

R392.1

DOI:

-

文献标志码:

A

摘要:

目的：探究IL-17A促进卵巢癌顺铂（DDP）耐药的体外机制。方法：应用流式细胞术分析外源性rhIL-17A对DDP诱导的A2780（顺铂敏感卵巢癌细胞株）和OVCAR3（顺铂耐药卵巢癌细胞株）细胞的凋亡和周期分布变化的影响，并以IL-17RAmAb进行相应的阻断实验。结果：rhIL-17A对A2780和OVCAR3细胞的凋亡无显著影响；但可显著降低DDP对A2780和OVCAR3细胞的毒性作用（P<0.05），以IL-17RAmAb进行阻断实验可部分消除rhIL-17A对DDP诱导的A2780和OVCAR3细胞凋亡的阻滞作用（P<0.05）。rhIL-17A对A2780和OVCAR3细胞的周期分布无显著影响；但可显著抑制 DDP诱导的A2780和OVCAR3细胞周期阻滞（P <0.05），使A2780和OVCAR3细胞的G0/G1期比例增加，G2+S期比例减少。结论： IL-17A可通过IL-17RA抑制DDP诱导的卵巢癌细胞凋亡，同时可抑制DDP诱导的卵巢癌细胞周期阻滞，从而加剧以DDP为基础的卵巢癌化疗耐药性。

Abstract:

Objective: To explore the underlying mechanisms of IL-17A promoting the cisplatin-based resistance of ovarian cancer. Methods: Flow cytometry assay was used to detect the effect of exogenous rhIL-17A on the cisplatin-based cell apoptosis and cycle distribution of A2780 and OVCAR3 cells, and then neutralizing IL-17RAmAb was applied to perform the blocking test. Results: RhIL-17A alone had no effect on the apoptosis of A2780 and OVCAR3 cells, but it could significantly inhibit the cytotoxicity of DDP to A2780 and OVCAR3 cells (P <0.05). Furthermore, neutralizing IL-17RAmAb could markedly block the above effect of rhIL-17A on DDP-sensitivity (P <0.05). There was no effect of rhIL-17A on cell cycle distribution of A2780 and OVCAR3 cells. After pre- treatment with rhIL-17A, the DDP effect on cell cycle might be changed partially by increasing the G0/G1 phase and decreasing the G2+S phase (P <0.05). Conclusion: IL-17A could inhibit the cisplatin-based cell apoptosis of ovarian cancer cell, partially through IL-17RA signal pathway. Moreover, IL-17A could also repress the effects of DDP on cell cycle distribution of ovarian cancer cell, which may provide a novel strategy to improve the chemoresistance of ovarian cancer.

参考文献/References:

[1] Gaffen S L. Structure and signalling in the IL-17 receptor family[J].Nat Rev Immunol,2009,9(8):556
[2] Moseley T A, Haudenschild D R, Rose L, et al. Interleukin-17 family and IL-17 receptors[J]. Cytokine Growth Factor Rev,2003,14(2):155
[3] Pollinger B, Junt T, Metzler B, et al. Th17 cells, not IL-17+gammadelta T cells, drive arthritic bone destruction in mice and humans[J]. J Immunol,2011,186(4):2602
[4] Stark M A, Huo Y Q, Burcin T L, et al. Phagocytosis of apoptotic neutrophils regulates granulopoiesis via IL-23 and IL-17[J]. FASEB, 2004,18(5, S):A827
[5] Buonocore S, Ahern P P, Uhlig H H, et al. Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology[J]. Nature,2010, 464(7293):1371
[6] Michel M L, Mendes-Da-Cruz D, Keller A C, et al. Critical role of ROR-γt in a new thymic pathway leading to IL-17-producing invariant NKT cell differentiation[J]. Proc Natl Acad Sci U S A, 2008, 105(50): 19845
[7] Ciric B, El-Behi M, Cabrera R, et al. IL-23 drives pathogenic IL-17-Producing CD8(+) T cells[J]. J Immunol, 2009, 182 (9):5296
[8] O’brien R L，Roark CL, born WK. IL-17-producing gammadelta T cells[J]. Eur J Immunol,2009,39(3):662
[9] Ohman A W, Hasan N, Dinulescu D M. Advances in tumor screening, imaging, and avatar technologies for high-grade serous ovarian cancer[J]. Front Oncol,2014,4:322
[10] Vargas A N. Natural history of ovarian cancer[J]. E Cancer Med Sci,2014,8:465
[11] Lim W, Song G. Discovery of prognostic factors for diagnosis and treatment of epithelial-derived ovarian cancer from laying hens[J]. J Cancer revent ,2013,18(3):209
[12] Niu X, Liu W, Wang Y, et al. IL-17A exacerbates cisplatin-based resistance of OVCA via upregulating the expression of ABCG2 and MDR1 through Gli1-mediated Hh signaling[J]. Oncotarget, 2016
[13] Chen Z J, Zhang Z, Xie B B, et al. Clinical significance of up-regulated lncRNA NEAT1 in prognosis of ovarian cancer[J]. Eur Rev Med Pharmacol Sci,2016,20(16):3373
[14] Wei F, Jiang X, Gao H Y, et al. Liquiritin induces apoptosis and autophagy in cisplatin (DDP)-resistant gastric cancer cells in vitro and xenograft nude mice in vivo[J]. Int J Oncol,2017,51(5):1383

相似文献/References:

[1]申彦,张新莹,师宜荃,等.Glut-1、HIF-1α及P53在卵巢癌中的表达及意义[J].天津医科大学学报,2013,19(05):383.
[2]周 闻,杨 臻,刘 民,等.抑癌基因ST7L对卵巢癌细胞增殖、细胞周期和裸鼠移植瘤的影响[J].天津医科大学学报,2016,22(05):373.
　ZHOU Wen,YANG Zhen,LIU Min,et al.Effects of ST7L on cell proliferation, cell cycle in ovarian cancer and tumour xenografts in nude mice[J].Journal of Tianjin Medical University,2016,22(03):373.
[3]范 丹,宋文静,张艳辉,等.PRRX1的表达对卵巢癌血管生成拟态形成及患者预后的影响[J].天津医科大学学报,2018,24(01):1.
　FAN Dan,SONG Wen-jing,ZHANG Yan-hui,et al.Effect of PRRX1 expression on VM formation and prognosis in ovarian cancer[J].Journal of Tianjin Medical University,2018,24(03):1.
[4]王雅蕾,王靖怡 综述,齐丽莎 审校.微环境在卵巢癌发生发展中的作用[J].天津医科大学学报,2020,26(03):288.
[5]李广宁 综述,曹文枫 审校.女性生殖系统双原发癌的研究进展[J].天津医科大学学报,2021,27(06):655.
[6]沈洋洋,牛秀珑,郁春艳,等.外源性IL-6 通过STAT3 通路促进卵巢癌细胞对顺铂 耐药[J].天津医科大学学报,2022,28(03):266.
　SHEN Yang-yang,NIU Xiu-long,YU Chun-yan,et al.Exogenous IL-6 promotes cisplatin resistance of ovarian cancer through STAT3 pathway[J].Journal of Tianjin Medical University,2022,28(03):266.
[7]李岩,牛秀珑,郁春艳,等.IL-17A可以促进卵巢癌的腹腔转移[J].天津医科大学学报,2020,26(06):518.
　LI Yan,NIU Xiu-long,YU Chun-yan,et al.IL-17A promotes intraperitoneal metastasis of ovarian cancer[J].Journal of Tianjin Medical University,2020,26(03):518.
[8]郑小燕,郁春艳,刘俊汝,等.IL-17A对卵巢癌进展的影响及机制研究[J].天津医科大学学报,2023,29(02):148.
　ZHENG Xiao-yan,YU Chun-yan,LIU Jun-ru,et al.Effect and mechanism of IL-17A on the progression of ovarian cancer[J].Journal of Tianjin Medical University,2023,29(03):148.

备注/Memo

备注/Memo:

文章编号 1006-8147(2018)03-0192-05
基金项目 天津市教委重点项目（2016YD01）；天津市科委应用基础研究项目（15JCYBJC26000）；武警后勤学院博士启动金项目资助（WHB201610）
作者简介 徐灵灵（1990-），女，硕士在读，研究方向：肿瘤免疫；通信作者：邓为民，E-mail:dengweimin@tmu.edu.cn。

常用功能

更新日期/Last Update: 2018-05-20